Issue 36 - Sep 27, 2019
  • An Appreciation

    Jerry D. Boyd, founding editor of The Cancer Letter, pioneer of cancer journalism, dies at 91

    Nearly half a century ago, Jerry Dock Boyd started covering the opening shots of the War on Cancer.

  • E-cigarette use rises in young adults as combustible cigarette use declines

    E-cigarette use is on the rise among young adults, but overall combustible cigarette use among teens is continuing on a downward trend, recent studies show.

  • Real-World Evidence

    Oncologists quickly react to label changes for immunotherapies, a study by Penn, Flatiron shows

    In an unprecedented use of real-world data, researchers at the University of Pennsylvania and Flatiron Health have determined that oncologists are responding quickly to label restrictions announced by FDA.

  • In Brief

    • Winship’s Curran receives ASTRO Gold Medal
    • Fairness to Kids with Cancer Act is introduced in the House
    • Brereton, Dornsife receive NCCS Stovall award
    • AdventHealth, Moffitt form collaboration
    • UMich and Karmanos get $9.2M prostate cancer SPORE grant
    • Six researchers receive $14M for cancer genomics research
    • Weitzel and Blazer win ASHG Arno Motulsky-Barton Childs Award
    • Jandial receives $1.35M DoD grant for LMD study
  • TCCL Logo

  • Trials & Tribulations

    Reducing re-excisions

    How intraoperative 3-D specimen tomosynthesis ensures fewer repeat breast cancer surgeries

    This year in the United States, nearly 270,000 women will receive the devastating news that they have breast cancer.  Many will choose breast-conserving surgery, commonly referred to as lumpectomy, wherein the surgeon seeks to remove the malignant tumor, while also preserving as much healthy breast tissue as possible.

  • Clinical Roundup

    • Breast cancer patients who exercise pre-diagnosis are at lower risk for heart disease
    • One in five young adults regularly uses e-cigarettes and believes they are harmless, not addictive
    • Univ. of Arizona researchers look to treat neuropathic pain caused by chemotherapy without using opioids.
  • Drugs & Targets

    • FDA approves Janssen’s Darzalex for new multiple myeloma indication
    • Cologuard gets FDA approval for use in younger patients indication
    • Astellas gets CHMP nod for Xospata as monotherapy for an AML indication
    • CHMP recommends approval for Bavencio + Axitinib for first-line treatment of advanced RCC
    • Celsius Therapeutics brings genomics platform to three institutions worldwide
    • Evotec, Takeda collaborate on drug discovery
    • Foundation Medicine, Natera to advance personalized cancer monitoring
    • Adaptive Biotechnologies, Amgen use clonoSEQ as preferred MRD test
Issue 35 - Sep 20, 2019
Issue 34 - Sep 13, 2019
  • Guest Editorial

    Why CAR-T policymaking is broken, and why we need to fix it

    The initial reports of the near-miraculous benefits of CAR-T in pediatric acute lymphoblastic leukemia generated tremendous excitement—there was a Lazarus-like quality to these stories.

  • The 2019 Lasker Awards go to: Max D. Cooper, Jacques Miller, Michael Shepard, Dennis J. Slamon, Axel Ullrich, and Gavi, the Vaccine Alliance

    The Lasker Foundation has named the winners of the 2019 Lasker Awards: Max D. Cooper, Jacques Miller, Michael Shepard, Dennis J. Slamon, Axel Ullrich, and Gavi, the Vaccine Alliance.

  • In Brief

    • DeAngelis named MSK physician-in-chief, chief medical officer
    • Bondy named chair of Stanford Epidemiology and Population Health Department
    • Farrar named CEO at Ohio State James Cancer Hospital and Solove Research Institute 
    • Yang appointed director of Division of Hematology at Ohio State 
    • Patierno receives AACR Distinguished Lectureship on the Science of Cancer Health Disparities
    • Samuel Waxman Cancer Research Foundation awards $1.4 million in grants
    • Purdue and Frederick National Laboratory form partnership focused on big data approach to cancer 
    • Bauml, Lai, and Lisberg receive LUNGevity 2019 Career Development Awards
    • UMN researchers awarded grant in metastatic breast cancer
    • Fortin departs Winship for UCLA Health
  • TCCL Logo

  • Conversation with The Cancer Letter

    Michigan’s Philip Stella receives NCORP 2019 Harry Hynes Award

    Philip J. Stella, the principal investigator of the Michigan Cancer Research Consortium NCI Community Oncology Research Program site in Ann Arbor, won the 2019 Harry Hynes Award.

  • Clinical Roundup

    • IMFINZI is first immunotherapy to show OS benefit,  improved, durable responses in extensive-stage SCLC 
    • Pooled five-year survival results show OS advantage for Opdivo in advanced NSCLC 
    • LOXO-292 shows 68% ORR, sustained durability in heavily pretreated RET fusion-positive NSCLC
    • ASTRO guideline clarifies role of radiation therapy in pancreatic cancer treatment
    • Study shows higher risk of death in patients with CV conditions who receive novel oral prostate cancer therapies 
  • Drugs & Targets

    • Adaptimmune receives Orphan Drug Designation for SPEAR T-cells targeting MAGE4-A in soft tissue sarcoma 
    • BioXcel receives Orphan Drug Designation for BXCL701 in AML